AI Article Synopsis
- The use of gadolinium-based contrast agents (GBCAs) is controversial, but Gd(III)-EOB-DTPA is still favored for its unique imaging capabilities related to the liver.
- Researchers developed a new liver-specific MRI probe called Mn(III)TriCP-PhOEt, which demonstrated higher relaxivity compared to Gd(III)-EOB-DTPA and specifically targets liver cells through Oatp1 channels.
- In experiments with mice, Mn(III)TriCP-PhOEt significantly enhanced liver imaging results and showed promise as an effective probe for in vivo studies.
Article Abstract
Controversy surrounding gadolinium-based contrast agents (GBCAs) has rendered their continued utility highly contentious, but the liver-specific GBCA Gd(III) ethoxybenzyl-diethylene triamine pentaacetic acid (Gd(III)-EOB-DTPA) remains in use because it provides unique diagnostic information that could not be obtained by any other means. To address the need for an alternate liver-specific MRI probe, we synthesized Mn(III) 20-(4-ethoxyphenyl) porphyrin-5,10,15-tricarboxylate (Mn(III)TriCP-PhOEt), which exhibited significantly higher relaxivity than Gd(III)-EOB-DTPA in vitro, while also targeting hepatocyte-specific organic anion-transporting polypeptide 1 (Oatp1) channels as a marker of viability. In mice, Mn(III)TriCP-PhOEt resulted in significant and specific increases in liver signal intensity on -weighted images and significant decreases in liver time relative to pre-contrast measurements. Our findings suggest that Mn(III)TriCP-PhOEt operates as a specific and sensitive MR probe for Oatp1-targeted imaging in vivo.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1021/acs.jmedchem.2c00500 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!